Expanded Germline Testing Reveals Clinically Relevant Overlap Across Hereditary Cancer Syndromes
Background: Despite the widespread implementation of BRCA1 and BRCA2 and mismatch repair testing, a substantial proportion of patients with suspected hereditary cancer remain without a molecular diagnosis. We evaluated the clinical utility of expanded germline testing in individuals with hereditary breast, ovarian and colorectal cancer susceptibility. Methods: Patients with suspected hereditary breast, ovarian, and colorectal cancer syndromes underwent multigene panel testing using the Ion S5™ System. Pathogenic and likely pathogenic variants were correlated with clinical and histopathological features. Results: Expanded germline testing identified clinically actionable pathogenic variants beyond BRCA1/2 and mismatch repair genes in 13% (146/1126) of high-risk families. Homologous recombination repair genes represented the largest subgroup of findings, with ATM emerging as the most prevalent non-BRCA susceptibility gene (3.7%). Among individuals fulfilling hereditary breast and ovarian cancer criteria, pathogenic variants in Lynch syndrome and polyposis genes were detected in 1.6% of cases, highlighting the limitations of phenotype-driven testing strategies. Additional pathogenic variants were identified in TP53, CDH1, CDKN2A, FANCM, NF1 and NBN, while concurrent mutations were detected in 1.15% of families. Conclusions: These findings demonstrate that a clinically relevant proportion of hereditary cancer susceptibility lies outside the classical BRCA1/2 and mismatch repair gene framework. Incorporating non-canonical susceptibility genes into routine testing increases diagnostic yield, identifies actionable cancer risk alleles and may refine surveillance, prevention and personalised management strategies in high-risk individuals.
Authors
- Noemí Martínez (ORCID: https://orcid.org/0000-0002-8628-7449)
- Lucía Mateo (ORCID: https://orcid.org/0009-0008-4273-1967)
- Amaya Olaverri
- Enrique Lastra (ORCID: https://orcid.org/0000-0001-8813-9733)
- Mónica Arranz-Ledo (ORCID: https://orcid.org/0000-0002-1707-4001)
- Mar Infante (ORCID: https://orcid.org/0000-0002-7197-5249)
- Lara Hernández (ORCID: https://orcid.org/0000-0002-7932-271X)
- Raquel Ferreira (ORCID: https://orcid.org/0009-0004-2653-3144)
- César Gutiérrez
- Mercedes Durán
Institutions
- Hospital Universitario de Burgos (ES)
- Instituto de Biomedicina y Genética Molecular de Valladolid (ES)
- Hospital Universitario Río Hortega (ES)
Publication Details
- Journal
- Medical Sciences
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3390/medsci14070790
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00